Latest News on DGX

Financial News Based On Company


Advertisement
Advertisement

Earnings Beat Might Change The Case For Investing In Stryker (SYK)

https://simplywall.st/stocks/us/healthcare/nyse-syk/stryker/news/earnings-beat-might-change-the-case-for-investing-in-stryker
Stryker (SYK) reported strong third-quarter results with 10.3% adjusted EPS growth driven by margin gains and cost control, particularly from Endoscopy, Medical, and Mako orthopaedics. The company is focusing on robotics and strategic board appointments to support its defensive growth narrative. Despite ongoing operational and sentiment risks like debt and insider selling, the latest performance indicates that Stryker's strategy remains effective.

McKesson Corporation (MCK) Stock Forecasts

https://ca.finance.yahoo.com/research/reports/ARGUS_3176_AnalystReport_1794855055000
Argus analyst David H. Toung has raised the target price for McKesson Corporation (MCK) stock, maintaining a "Buy" rating. The report, published on November 16, 2026, highlights McKesson's operations across North American Pharmaceutical, Oncology & Multispecialty, Prescription Technology Solutions, and Medical-Surgical segments.

Quest Diagnostics Inc. stock outperforms competitors on strong trading day

https://www.marketwatch.com/data-news/quest-diagnostics-inc-stock-outperforms-competitors-on-strong-trading-day-2a4ebe01-d8612db35e03?mod=mw_quote_news
Quest Diagnostics Inc. (DGX) shares rose 1.30% to $259.69 on Wednesday, outperforming the broader market which saw the S&P 500 Index and Dow Jones Industrial Average decline. The company's stock closed 1.33% below its 52-week high of $263.19, achieved just two days prior.

Labcorp selected for biomarker testing in Florida prostate-cancer study

https://mugglehead.com/labcorp-otraces-florida-prostate-cancer-biomarker-study/
Labcorp has been selected by OTraces to perform biomarker testing for a Florida prostate-cancer study involving approximately 950 men, funded by a US$2 million state grant. The study aims to evaluate OTraces' platform's ability to predict biopsy outcomes better than standard PSA testing and distinguish aggressive from indolent disease. This partnership follows Labcorp's recent agreement to acquire 4Kscore, an existing prostate-cancer blood test, from OPKO Health, Inc.

Two $10M stock awards are set to follow the CEO handoff at GeneDx (WGS).

https://www.stocktitan.net/sec-filings/WGS/8-k-gene-dx-holdings-corp-reports-material-event-4f37456eaa52.html
GeneDx Holdings Corp. (WGS) has appointed Everett Cunningham as its new CEO, effective on or before December 15, 2026. Katherine Stueland will step down as CEO and a director but will remain as an Executive Advisor through January 31, 2027. Cunningham's compensation package includes a $750,000 annual base salary, a target annual cash bonus of 100% of his base salary, a $1,050,000 sign-on bonus, and two $10.0 million equity awards, one time-based and one performance-based.
Advertisement

Quest Diagnostics Inc. stock outperforms competitors despite losses on the day

https://www.marketwatch.com/data-news/quest-diagnostics-inc-stock-outperforms-competitors-despite-losses-on-the-day-baf1a390-e9a73efd3dbf
Quest Diagnostics Inc. (DGX) shares dropped 2.23% to $256.35 on Tuesday, performing better than the overall market which saw the S&P 500 Index (SPX) fall 1.03% and the Dow Jones Industrial Average (DJIA) fall 1.64%. The company's stock closed 2.60% below its 52-week high of $263.19, achieved on November 16th.

When Will Quest Diagnostics (NYSE:DGX) Pay Its Quarterly Dividend?

https://kalkinemedia.com/us/stocks/bluechip/when-will-quest-diagnostics-nysedgx-pay-its-quarterly-dividend
Quest Diagnostics (NYSE:DGX) has declared a quarterly cash dividend that will be payable in January of next year to shareholders registered by January of next year. This announcement follows a period of strong third-quarter revenue growth, with increased requisition volumes and raised full-year revenue and earnings guidance. The company has also made strategic advancements in consumer access through the Apple Health app, expanded its hospital outreach, and introduced new specialized testing and digital tools like the Quest AI Companion.

Quest Diagnostics Inc. stock underperforms Monday when compared to competitors despite daily gains

https://www.marketwatch.com/data-news/quest-diagnostics-inc-stock-underperforms-monday-when-compared-to-competitors-despite-daily-gains-cdf69306-770e5f3572bd
Quest Diagnostics Inc. (DGX) stock rose 1.01% to $262.21 on Monday, setting a new 52-week high, despite an overall negative trading day for the broader market. The S&P 500 Index and Dow Jones Industrial Average both experienced significant declines. Despite its gains, the stock underperformed when compared to its competitors.

VivoSim Labs to present liver and intestine toxicity data at ACT meeting

https://www.streetinsider.com/Corporate+News/VivoSim+Labs+to+present+liver+and+intestine+toxicity+data+at+ACT+meeting/27348959.html
VivoSim Labs, Inc. (Nasdaq: VIVS) announced it will present two studies at the 2026 American College of Toxicology Annual Meeting, focusing on liver and gastrointestinal toxicity. The presentations will showcase data from their NAMkind™ Liver and NAMkind™ Intestine platforms, which utilize 3D human cellular models to assess drug toxicity. These platforms aim to identify drug-induced organ injury more effectively than traditional animal models, particularly for compounds that failed in human clinical trials due to liver or GI toxicity.

Three customers account for all Q3 revenue as Scienture Holdings (SCNX) posts a wider loss.

https://www.stocktitan.net/sec-filings/SCNX/10-q-scienture-holdings-inc-quarterly-earnings-report-48ffcdfe346e.html
Scienture Holdings (SCNX) reported a widened net loss of $6.01 million in Q3 2026, despite a significant increase in revenue to $1.25 million, primarily driven by sales of its new products, REZENOPY™ and ARBLI™. The company's revenue heavily relies on three wholesale distributors, which accounted for all Q3 revenue, highlighting customer concentration risk. While management believes existing cash and planned financing will sustain operations for at least 12 months, continued success depends on product adoption and securing additional capital.
Advertisement

Stryker (SYK) Board Refresh And Financing Flexibility Put Valuation Back In Focus

https://simplywall.st/stocks/us/healthcare/nyse-syk/stryker/news/stryker-syk-board-refresh-and-financing-flexibility-put-valu
Stryker (SYK) is undergoing a board refresh with a new director joining in early 2027 and has filed a shelf registration for future financing flexibility. This comes as the company's stock has been under pressure, with shares down over 11% year-to-date. Despite the market's skepticism, the article highlights Stryker's strong earnings growth, robust cash flow, and positioning in the medical technology sector, suggesting a potential sentiment reset rather than a fundamental flaw in the business.

Reflecting on testing & diagnostics services stocks’ Q3 earnings: Guardant Health

https://www.tradingview.com/news/stockstory:ab8e6c3ea094b:0-reflecting-on-testing-diagnostics-services-stocks-q3-earnings-guardant-health/
This article reviews the Q3 earnings of testing & diagnostics services stocks, focusing on Guardant Health (GH) which reported strong revenue growth and exceeded analyst expectations. It also highlights the performance of other companies in the sector, including NeoGenomics (NEO), Quest Diagnostics (DGX), Labcorp (LH), and RadNet (RDNT), detailing their revenue, growth, and market reactions. The sector as a whole experienced solid Q3 results with revenues beating consensus estimates.

Quest settles federal claims over VIP Giants access for doctors

https://giantswire.usatoday.com/story/sports/nfl/giants/2026/11/15/quest-settles-federal-claims-over-vip-giants-access-doctors/92793961007/
Quest Diagnostics, Inc. has agreed to pay over $13 million to resolve federal allegations of submitting false claims to Medicare and Medicaid programs. The company allegedly provided illegal kickbacks, including VIP access to New York Giants games and events, to healthcare providers and executives to induce patient referrals. This settlement stems from a whistleblower lawsuit and includes a five-year Corporate Integrity Agreement.

Missed NeoGenomics' Rally? Here's What Buyers Saw

https://simplywall.st/stocks/us/healthcare/nasdaq-neo/neogenomics/news/missed-neogenomics-rally-heres-what-buyers-saw
NeoGenomics' stock has seen a 54.9% return over the past year, prompting investors to consider what drove this rally. While a bullish narrative focused on aging populations and digital health tools driving oncology testing suggested a fair value of US$14, a bearish view highlighted margin pressures and regulatory risks. Recent Q3 2026 results showed improved revenue and narrowed losses, supporting the bullish thesis, though profitability remains unproven.

Quest Diagnostics SVP Plewman sells $3.01 million in stock By Investing.com

https://in.investing.com/news/stock-market-news/quest-diagnostics-svp-plewman-sells-301-million-in-stock-93CH-5701502
Patrick Plewman, SVP for Diagnostic Services at Quest Diagnostics Inc. (NASDAQ:DGX), sold approximately $3.01 million worth of common stock on November 9, 2026. These sales followed an acquisition of shares through option exercises, all executed under a Rule 10b5-1 trading plan. The insider sale occurred as the stock neared its 52-week high, with InvestingPro analysis suggesting it is overvalued, despite the company's strong third-quarter 2026 results.
Advertisement

Quest Diagnostics SVP Plewman sells $3.01 million in stock

https://www.investing.com/news/insider-trading-news/quest-diagnostics-svp-plewman-sells-301-million-in-stock-93CH-5023842
Patrick Plewman, SVP for Diagnostic Services at Quest Diagnostics Inc. (NASDAQ:DGX), sold approximately $3.01 million worth of common stock on November 9, 2026. These sales followed the exercise of non-qualified stock options and were executed under a Rule 10b5-1 trading plan. The insider sale occurs as the stock trades near its 52-week high, with InvestingPro analysis suggesting it is overvalued.

Quest Diagnostics SVP Plewman sells $3.01 million in stock By Investing.com

https://ca.investing.com/news/stock-market-news/quest-diagnostics-svp-plewman-sells-301-million-in-stock-93CH-4954977
Patrick Plewman, Senior Vice President at Quest Diagnostics (NASDAQ:DGX), sold approximately $3.01 million worth of common stock on November 9, 2026, as part of a Rule 10b5-1 trading plan. This followed his acquisition of shares through stock option exercises. The insider sale occurred while Quest Diagnostics stock was near its 52-week high, with InvestingPro analysis indicating the stock might be overvalued despite the company's strong Q3 2026 earnings report and raised full-year outlook.

Form 4 Quest Diagnostics Incorporated: Patrick Plewman (SVP for Diagnostic Services) For: 9 November By Investing.com

https://in.investing.com/news/stock-market-news/form-4-quest-diagnostics-orporated-patrick-plewman-svp-for-diagnostic-services-for-9-november-93CH-5701511
This article reports on a Form 4 filing for Quest Diagnostics (DGX) concerning Patrick Plewman, the Senior Vice President for Diagnostic Services, for activity on November 9. Form 4 filings disclose changes in beneficial ownership of securities by a company's insiders. The article indicates a 0.37% movement in DGX shares.

Under trading plans, Quest Diagnostics (DGX) SVP sells 11,717 shares at $257.34.

https://www.stocktitan.net/sec-filings/DGX/form-4-quest-diagnostics-inc-insider-trading-activity-dcc60a15c6e7.html
Patrick Plewman, SVP for Diagnostic Services at Quest Diagnostics Inc. (DGX), sold 11,717 common shares at $257.34 per share on November 9, 2026. This transaction was part of Rule 10b5-1 sales plans, following the exercise of options for 4,274 shares at $127.725 and 6,793 shares at $127.805. After the transaction, Plewman holds 14,684 common shares directly.

Form 4 QUEST DIAGNOSTICS INC For: Nov 09 Filed by: Plewman Patrick

https://www.streetinsider.com/SEC+Filings/Form+4+QUEST+DIAGNOSTICS+INC+For%3A+Nov+09+Filed+by%3A+Plewman+Patrick/27338125.html
This article details a Form 4 filing for Quest Diagnostics Inc. (DGX) by Patrick Plewman, SVP for Diagnostic Services. The filing reports transactions on November 9, 2026, including the exercise of non-qualified stock options and the sale of common stock, executed under a Rule 10b5-1 sales plan. The transactions resulted in changes in Plewman's direct beneficial ownership of Quest Diagnostics common stock.
Advertisement

bioAffinity Technologies Advances CyPath Lung for Lung Cancer Survivor Surveillance

https://www.mpo-mag.com/breaking-news/bioaffinity-technologies-advances-cypath-lung-for-lung-cancer-survivor-surveillance/
bioAffinity Technologies is exploring the use of its CyPath Lung test to monitor lung cancer patients who have completed curative-intent treatment, aiming to detect recurrence earlier. The noninvasive test, which uses flow cytometry and AI to identify malignant cells in sputum, can complement imaging by providing additional information on pulmonary nodules, helping physicians determine the need for further investigation versus continued surveillance. This initiative builds on CyPath Lung's proven ability to detect early-stage lung cancer and could significantly improve patient outcomes by enabling earlier intervention.

Cintas/UniFirst: CFO Expresses Confidence in Deal Prospects as FTC Review Continues

https://thecapitolforum.com/cintas-unifirst-cfo-expresses-confidence-in-deal-prospects-as-ftc-review-continues/
Cintas CFO Scott Garula indicated confidence in the company's proposed $5.5 billion acquisition of UniFirst, despite ongoing engagement with the FTC regarding the deal. The announcement was made at an industry conference in Chicago. This suggests that Cintas is actively working with regulators to address any concerns.

Form 144 QUEST DIAGNOSTICS INC For: 11 November By Investing.com

https://ca.investing.com/news/stock-market-news/form-144-quest-diagnostics-inc-for-11-november-93CH-4950985
This article announces the filing of Form 144 for Quest Diagnostics Inc. on November 11, 2026. Form 144 is a notice of the intent to sell restricted securities, indicating potential insider activity or significant share transactions. The brief report highlights the company's stock symbol DGX and mentions a slight positive change in its stock price.

Form 144 QUEST DIAGNOSTICS INC For: 11 November By Investing.com

https://uk.investing.com/news/stock-market-news/form-144-quest-diagnostics-inc-for-11-november-93CH-4975698
This article from Investing.com announces a Form 144 filing for QUEST DIAGNOSTICS INC (DGX) on November 11. Form 144 is filed with the SEC by an affiliate of a company who intends to sell restricted or controlled securities. The article provides the basic announcement without further details on the filing's specifics.

Quest Diagnostics Declares Quarterly Cash Dividend

https://www.tradingview.com/news/prnewswire:2c9dff8fac081:0-quest-diagnostics-declares-quarterly-cash-dividend/
Quest Diagnostics (DGX) announced that its Board of Directors has declared a quarterly cash dividend of $0.86 per share. This dividend is payable on January 27, 2027, to shareholders of record of Quest Diagnostics common stock as of January 12, 2027. Quest Diagnostics is a leading provider of diagnostic information services, serving a significant portion of physicians, hospitals, and American adults annually.
Advertisement

QuidelOrtho launches VITROS 450 waterless chemistry testing for low-volume laboratories

https://www.selectscience.net/article/quidelortho-launches-vitros-450-waterless-chemistry-testing-for-low-volume-laboratories
QuidelOrtho Corporation has launched the VITROS 450 Chemistry System in key global markets, offering a compact, waterless analyzer for low-volume and community-based laboratories. This system utilizes MicroSlide™ technology to provide high-quality, reliable chemistry testing, particularly benefiting settings with limited water, space, or staffing. The launch aims to advance diagnostic access and quality across diverse healthcare environments by offering a sustainable and user-friendly solution.

bioAffinity Technologies Reports Record Monthly Testing Volume in October for Its Noninvasive CyPath® Lung Test

https://sg.finance.yahoo.com/news/bioaffinity-technologies-reports-record-monthly-130000421.html
bioAffinity Technologies announced a record-high monthly testing volume for its noninvasive CyPath® Lung test in October 2026, with 235 tests performed. This represents a 29% increase from October 2025 and equals approximately 45% of the total tests from Q3 2026. The company attributes this growth to expanded commercial reach, increased physician adoption, and efforts to strengthen relationships within the lung cancer community.

Stryker Board Expands with Healthcare Executive James Davis

https://www.theglobeandmail.com/investing/markets/stocks/SYK/pressreleases/8769863/stryker-board-expands-with-healthcare-executive-james-davis/
Stryker's board of directors has been expanded from 11 to 12 members with the election of James E. Davis. Davis, the CEO and President of Quest Diagnostics, brings extensive experience from across the healthcare, medical technology, and global operations sectors. Analysts maintain a "Buy" rating on Stryker (SYK) stock with a $350.00 price target, while TipRanks' AI Analyst, Spark, rates SYK as "Outperform" due to strong financial performance.

Learn Why The Bull Case For Guardant Health Stock Could Change Following Revenue Guidance Raise

https://simplywall.st/stocks/us/healthcare/nasdaq-gh/guardant-health/news/learn-why-the-bull-case-for-guardant-health-stock-could-chan
Guardant Health (NasdaqGS:GH) reported Q3 2026 sales of US$360.98 million and raised its full-year 2026 revenue guidance to US$1.36 to US$1.37 billion due to strong demand for its cancer screening and oncology tests. While this revenue growth supports the bullish narrative, the company continues to report significant net losses, keeping focus on cash burn and the path to profitability. Analyst models project rapid revenue expansion and a sharp swing to profitability over the next few years, but also factor in dilution and a rich valuation.

Quest Diagnostics Declares Quarterly Cash Dividend

https://www.prnewswire.com/news-releases/quest-diagnostics-declares-quarterly-cash-dividend-302935557.html
Quest Diagnostics (NYSE: DGX) has announced that its Board of Directors declared a quarterly cash dividend of $0.86 per share. This dividend is payable on January 27, 2027, to shareholders of record as of January 12, 2027. Quest Diagnostics is a leading provider of diagnostic information services, serving a significant portion of physicians, hospitals, and adults in the United States.
Advertisement

Form SCHEDULE 13G QUEST DIAGNOSTICS INC Filed by: STATE STREET CORP

https://www.streetinsider.com/SEC+Filings/Form+SCHEDULE+13G+QUEST+DIAGNOSTICS+INC+Filed+by%3A+STATE+STREET+CORP/27320325.html
State Street Corporation has filed a Schedule 13G form with the SEC, indicating its beneficial ownership of 5% of Quest Diagnostics Inc.'s common stock. The filing details that State Street Corporation has shared voting power over 3,406,108 shares and shared dispositive power over 5,557,626 shares, totaling an aggregate beneficial ownership of 5,563,421 shares. This statement certifies that the securities were acquired in the ordinary course of business and not for the purpose of influencing control of the issuer.

One holder reports 5% of Quest Diagnostics (DGX), with no sole voting power.

https://www.stocktitan.net/sec-filings/DGX/schedule-13g-quest-diagnostics-inc-passive-investment-disclosure-5-0a3bcc444a19.html
State Street Corporation has reported a 5% beneficial ownership stake in Quest Diagnostics Inc. (DGX), holding 5,563,421 common shares. The filing indicates that State Street Corporation has shared voting power over 3,406,108 shares and shared dispositive power over 5,557,626 shares, but no sole voting or dispositive power. This Schedule 13G filing highlights State Street's passive investment in Quest Diagnostics.

Stryker nominates Quest Diagnostics CEO to board

https://www.investing.com/news/company-news/stryker-nominates-quest-diagnostics-ceo-to-board-93CH-5013217
Stryker's board of directors has nominated Jim Davis, the current Chairman, CEO, and President of Quest Diagnostics, for election to its board, effective January 1, 2027. Davis brings extensive healthcare experience, operational leadership, and medical technology understanding from his previous roles at InSightec, General Electric, and McKinsey & Company. Stryker's Chair and CEO, Kevin Lobo, highlighted Davis's expertise as a strong addition to the company's strategic advancement.

Quest Diagnostics CFO Sam Samad to Present at Evercore Healthcare Conference on December 1, 2026

https://kalkinemedia.com/us/news/announcements/quest-diagnostics-cfo-sam-samad-to-present-at-evercore-healthcare-conference-on-december-1-2026
Quest Diagnostics Incorporated announced that its Executive Vice President and CFO, Sam Samad, will participate in a fireside chat at the 9th Annual Evercore Healthcare Conference on December 1, 2026. The event will take place in Miami at 2:10 p.m. Eastern Time and will be webcast live on the company's investor relations website, with an archived version available until December 15, 2026.

Stryker announces intention to nominate Jim Davis to board of directors

https://www.globenewswire.com/news-release/2026/11/09/3398968/0/en/stryker-announces-intention-to-nominate-jim-davis-to-board-of-directors.html
Stryker (NYSE:SYK) announced its intention to nominate Jim Davis, Chairman, CEO, and President of Quest Diagnostics, to its board of directors, effective January 1, 2027. Davis brings extensive leadership experience from healthcare, medical technology, and global operations, including previous roles at InSightec, Inc., General Electric, and McKinsey & Company, Inc. Kevin Lobo, Stryker's Chair and CEO, highlighted Davis's deep healthcare experience, operational leadership, and understanding of medical technology as valuable additions to the company's strategic advancement.
Advertisement

Stryker nominates Quest Diagnostics CEO Jim Davis to its board

https://www.streetinsider.com/Board+Changes/Stryker+nominates+Quest+Diagnostics+CEO+Jim+Davis+to+its+board/27314889.html
Stryker has nominated Jim Davis, the current Chairman, CEO, and President of Quest Diagnostics, to its board of directors, effective January 1, 2027. Davis brings extensive healthcare, operational, and medical technology experience from his roles at Quest, InSightec, GE, and McKinsey & Company. Kevin Lobo, Stryker's Chair and CEO, expressed enthusiasm for Davis's potential contributions to the company's strategy and mission.

Quest Diagnostics to Speak at the 9th Annual Evercore Healthcare Conference

https://www.prnewswire.com/news-releases/quest-diagnostics-to-speak-at-the-9th-annual-evercore-healthcare-conference-302933631.html
Quest Diagnostics announced that Sam Samad, Executive Vice President and Chief Financial Officer, will participate in a fireside chat at the 9th Annual Evercore Healthcare Conference on December 1, 2026. The session will be webcast live on the company's investor relations page and an archived version will be available afterward. Quest Diagnostics is a leader in diagnostic information services, serving a large portion of U.S. physicians, hospitals, and adults.

Quest Diagnostics' chief financial officer will speak live from London on Nov. 17

https://www.stocktitan.net/news/DGX/quest-diagnostics-to-speak-at-the-jefferies-global-healthcare-wjpxb84l2l5f.html
Quest Diagnostics (NYSE: DGX) announced that Sam Samad, Executive Vice President and Chief Financial Officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference in London on November 17, 2026, at 8:30 a.m. Eastern Time. The session will be webcast live on the company's investor relations page, and an archived version will be available for a limited time after the event. This participation provides an opportunity for investors and stakeholders to gain insights into the company's financial strategies and outlook.

RadNet Q3 2026 Earnings Call Transcript

https://www.benzinga.com/news/26/11/63051234/radnet-q3-2026-earnings-call-transcript
RadNet, Inc. reported record third-quarter revenue of $683 million, a 22.1% increase year-over-year, and adjusted EBITDA of $105 million, a 23.8% increase, driven by demand in advanced imaging, new centers, and joint ventures. The company announced the acquisition of ONRAD, forming a new Radiology Professional Services segment, expected to add significant revenue and EBITDA. RadNet also raised its 2026 full-year guidance for Imaging Center revenue, adjusted EBITDA, and free cash flow due to strong performance and digital health growth.

Form 144 QUEST DIAGNOSTICS INC Filed by: Plewman Patrick

https://www.streetinsider.com/SEC+Filings/Form+144+QUEST+DIAGNOSTICS+INC+Filed+by%3A+Plewman+Patrick/27312984.html
Patrick Plewman, an officer of Quest Diagnostics Inc., has filed a Form 144 indicating his intent to sell 11,717 shares of common stock on November 9, 2026, with an aggregate market value of $3,015,252.78. The filing details the acquisition of these securities, including shares from restricted stock vesting in February 2025 and stock option exercise on the sale date. Fidelity Brokerage Services LLC is named as the broker for the transaction.
Advertisement

Officer Patrick Plewman plans to sell 11,717 Quest Diagnostics (DGX) shares.

https://www.stocktitan.net/sec-filings/DGX/144-quest-diagnostics-inc-sec-filing-ff897bfb52dd.html
Quest Diagnostics officer Patrick Plewman intends to sell 11,717 common shares of DGX, valued at approximately $3.02 million, with an approximate sale date of November 9, 2026. The shares were acquired through restricted stock vesting and a stock option exercise, with a Rule 10b5-1 plan adopted on August 11, 2026. This transaction is detailed in a Form 144 SEC filing.

Twist Bioscience’s CEO and CFO will appear in live webcasts, with replays available for 30 days.

https://www.stocktitan.net/news/TWST/twist-bioscience-to-present-at-upcoming-investor-igm2j2l19dn0.html
Twist Bioscience (NASDAQ: TWST) announced that its CEO, Emily M. Leproust, Ph.D., and CFO, Adam Laponis, will participate in upcoming investor conferences. They are scheduled for fireside chats at the Jefferies Global Healthcare Conference on November 17 and the 9th Annual Evercore Healthcare Conference on December 1. Live webcasts of these sessions will be available on the company's investor relations page, with replays accessible for 30 days.

Quest Diagnostics to Speak at the Jefferies Global Healthcare Conference in London

https://www.prnewswire.com/news-releases/quest-diagnostics-to-speak-at-the-jefferies-global-healthcare-conference-in-london-302933630.html
Quest Diagnostics (NYSE: DGX) announced that Sam Samad, Executive Vice President and CFO, will participate in a fireside chat at the Jefferies Global Healthcare Conference in London on November 17, 2026, at 8:30 a.m. Eastern Time. The session will be webcast live on the company's investor relations page, with an archived version available afterward until December 1, 2026.

Secaucus-Based Quest Diagnostics Fined $13 Million For Alleged Kickback Violations

https://patch.com/new-jersey/secaucus/secaucus-based-quest-diagnostics-fined-13-million-alleged-kickback-violations
Quest Diagnostics, headquartered in Secaucus, has agreed to pay a $13 million fine to resolve allegations of providing illegal kickbacks to doctors and executives. Prosecutors claimed Quest offered perks like suite tickets to MetLife Stadium in exchange for business, which Quest denies, stating the events were transparent and compliant. The settlement, which Quest accepted to put the matter behind them, resolves allegations of violating the Anti-Kickback statute from 2013 to 2022.

Quest Diagnostics Quanum Breach: Check Patient Data Exposure

https://homeland411.com/quest-diagnostics-quanum-breach-patient-exposure/
Quest Diagnostics disclosed a data breach on its Quanum Lab Services Manager platform, exposing patient names, birthdates, lab requisitions, and diagnostic result metadata. The incident occurred on October 21, 2026, leading to a five-day portal outage. Patients are advised to audit MyQuest history, confirm provider Quanum usage, monitor HIPAA notices, and enforce credit freezes to protect their information.
Advertisement

Quest Diagnostics pays $13M to settle allegations tied to Giants ticket perks

https://newjersey.news12.com/2026/11/08/quest-diagnostics-pays-13m-to-settle-allegations-tied-to-giants-ticket-perks/2CrKSPBb3pAcbF9ISr022D
Quest Diagnostics, based in Secaucus, has paid over $13 million to settle allegations of violating federal anti-kickback laws. Prosecutors claimed the company provided free entertainment, including New York Giants tickets, to healthcare decision-makers to induce laboratory testing referrals. Quest denied wrongdoing but agreed to the settlement and a five-year Corporate Integrity Agreement to resolve the dispute.

Form 144 QUEST DIAGNOSTICS INC For: 8 November By Investing.com

https://ng.investing.com/news/stock-market-news/form-144-quest-diagnostics-inc-for-8-november-93CH-2792249
This article announces the filing of Form 144 for Quest Diagnostics Inc. on November 8, 2026. The brief notice from Investing.com indicates the public disclosure of an intent to sell restricted securities by affiliates of the company. It includes a general stock market snapshot and related articles, though no specific details of the Form 144 filing are provided within this particular news item.

Form 144 QUEST DIAGNOSTICS INC For: 8 November By Investing.com

https://in.investing.com/news/stock-market-news/form-144-quest-diagnostics-inc-for-8-november-93CH-5689069
This article announces the filing of Form 144 for Quest Diagnostics Inc. on November 8, 2026. Form 144 is a notice of the intent to sell restricted securities. The report provides basic details about the filing for the company, identified by the stock symbol DGX.

Form 144 QUEST DIAGNOSTICS INC For: 8 November By Investing.com

https://uk.investing.com/news/stock-market-news/form-144-quest-diagnostics-inc-for-8-november-93CH-4966775
This article announces the filing of Form 144 for Quest Diagnostics Inc., dated November 8th. Form 144 is a notice of the intent to sell restricted stock. The article itself provides minimal detail beyond this announcement, indicating it is a standard regulatory filing notification.

Quest Diagnostics pays $13M to settle allegations tied to Giants ticket perks

https://newjersey.news12.com/quest-diagnostics-pays-13m-to-settle-allegations-tied-to-giants-ticket-perks
Quest Diagnostics Inc. has agreed to pay over $13 million to resolve allegations that it violated federal anti-kickback laws. Prosecutors alleged the Secaucus-based company provided free entertainment, including New York Giants tickets, to healthcare decision-makers to induce referrals for laboratory testing services. Quest denied wrongdoing, stating it settled to put the dispute behind it.
Advertisement
Advertisement
Advertisement
Advertisement

Sign Up free to view live trades and discussion forum to make more informed financial decisions. No credit card is required for sign up!
View Daily Trades
Join Discussion

Advertisement
Advertisement
Advertisement
Advertisement